On Wednesday, Shares of Bank of America Corporation (NYSE:BAC), gained 0.39% to $17.87.
The world’s top professional wheelchair athletes will go head-to-head in the first Chicago-New York Challenge; it was declared by Carey Pinkowski, executive race director of the Bank of America Chicago Marathon and Peter Ciaccia, president of events for New York Road Runners and race director of the TCS New York City Marathon.
Defending Bank of America Chicago Marathon champions Tatyana McFadden and Josh George will headline a deep professional field competing in the challenge, which will serve as a prelude to the inaugural Abbott World Marathon Majors Wheelchair Series starting with the Boston Marathon in April 2016. A $10,000 winner-take-all prize will be awarded to the male and female with the most points earned in the 2015 Bank of American Chicago Marathon on Sunday, October 11 and the 2015 TCS New York City Marathon on Sunday, November 1.
Last year’s top finishers and those returning to the 2015 Bank of America Chicago Marathon race comprise Kurt Fearnley (AUS), Ernst Van Dyk (RSA), Amanda McGrory (USA) and Manuela Schar (SUI), and reigning champions Josh George (USA) and Tatyana McFadden (USA).
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 3.39% to $17.67, during its last trading session.
Endo International plc (ENDP) declared the completion of the formerly declared sale of its American Medical Systems’ (AMS) Men’s and Prostate Health businesses to Boston Scientific (BSX) for a purchase price of up to $1.65 billion, with $1.60 billion in cash having been paid by Boston Scientific to Endo at closing. As formerly declared, Endo is also eligible to receive a potential milestone payment of $50 million in cash conditioned on the achievement of certain product revenue milestones in the Men’s Health and Prostate Health businesses in 2016.
BofA Merrill Lynch served as financial advisor to Endo. Skadden, Arps, Slate, Meagher & Flom LLP serves as its legal advisor.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Finally, Baxalta Incorporated (NYSE:BXLT), ended its last trade with 0.54% gain, and closed at $37.30.
Shire plc confirmed that it made a proposal to Baxalta Incorporated (BXLT) on July 10, 2015, to combine the companies in an all-stock transaction following which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire ADRs. The proposal implies a value of $45.23 per Baxalta share and represents a noteworthy premium of 36% over Baxalta’s stock price as of August 3, 2015. Baxalta has declined to engage in substantive discussions regarding the proposal.
The projected combination would generate immediate shareholder value and accelerate the growth plans of both Shire and Baxalta. The combined entity would be the global leader in rare diseases with multiple billion-dollar franchises in high-value therapeutic areas with substantial barriers to entry. Together, Baxalta and Shire are projected to deliver product sales of $20 billion in 2020, advancing the combined pipeline and bringing innovative new therapies to market for patients with rare, often life-threatening, diseases and conditions.
The projected transaction would be structured as an all-stock transaction to maintain the tax-free nature of Baxalta’s July 1, 2015, spinoff from Baxter. Baxalta shareholders would own about 37% of the combined Shire group.
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
